274 related articles for article (PubMed ID: 32480195)
1. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
[TBL] [Abstract][Full Text] [Related]
2. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Arita H; Yamasaki K; Matsushita Y; Nakamura T; Shimokawa A; Takami H; Tanaka S; Mukasa A; Shirahata M; Shimizu S; Suzuki K; Saito K; Kobayashi K; Higuchi F; Uzuka T; Otani R; Tamura K; Sumita K; Ohno M; Miyakita Y; Kagawa N; Hashimoto N; Hatae R; Yoshimoto K; Shinojima N; Nakamura H; Kanemura Y; Okita Y; Kinoshita M; Ishibashi K; Shofuda T; Kodama Y; Mori K; Tomogane Y; Fukai J; Fujita K; Terakawa Y; Tsuyuguchi N; Moriuchi S; Nonaka M; Suzuki H; Shibuya M; Maehara T; Saito N; Nagane M; Kawahara N; Ueki K; Yoshimine T; Miyaoka E; Nishikawa R; Komori T; Narita Y; Ichimura K
Acta Neuropathol Commun; 2016 Aug; 4(1):79. PubMed ID: 27503138
[TBL] [Abstract][Full Text] [Related]
3. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
4. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry.
Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T
Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470
[TBL] [Abstract][Full Text] [Related]
5. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
6. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
8. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
9. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
10. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
Minniti G; Scaringi C; Arcella A; Lanzetta G; Di Stefano D; Scarpino S; Bozzao A; Pace A; Villani V; Salvati M; Esposito V; Giangaspero F; Enrici RM
J Neurooncol; 2014 Jun; 118(2):377-383. PubMed ID: 24748470
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis.
Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH
Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902
[TBL] [Abstract][Full Text] [Related]
13. Telomerase reverse transcriptase promoter mutation- and O
Gramatzki D; Felsberg J; Hentschel B; Wolter M; Schackert G; Westphal M; Regli L; Thon N; Tatagiba M; Wick W; Schlegel U; Krex D; Matschke J; Roth P; Suresh MP; Kamp MA; Rushing EJ; Pietsch T; von Deimling A; Sabel M; Loeffler M; Weller M; Reifenberger G
Eur J Cancer; 2021 Apr; 147():84-94. PubMed ID: 33631540
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy plus concomitant temozolomide in primary gliosarcoma.
Adeberg S; Bernhardt D; Harrabi SB; Diehl C; Koelsche C; Rieken S; Unterberg A; von Deimling A; Debus J
J Neurooncol; 2016 Jun; 128(2):341-8. PubMed ID: 27025857
[TBL] [Abstract][Full Text] [Related]
15. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
[TBL] [Abstract][Full Text] [Related]
16. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
Etcheverry A; Aubry M; Idbaih A; Vauleon E; Marie Y; Menei P; Boniface R; Figarella-Branger D; Karayan-Tapon L; Quillien V; Sanson M; de Tayrac M; Delattre JY; Mosser J
PLoS One; 2014; 9(9):e104455. PubMed ID: 25233099
[TBL] [Abstract][Full Text] [Related]
17. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
18. Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.
Malmström A; Poulsen HS; Grønberg BH; Stragliotto G; Hansen S; Asklund T; Holmlund B; Łysiak M; Dowsett J; Kristensen BW; Söderkvist P; Rosell J; Henriksson R;
Acta Oncol; 2017 Dec; 56(12):1776-1785. PubMed ID: 28675067
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
20. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
